.Pharmacolibrary.Drugs.ATC.R.R01AA05 .Pharmacolibrary.Drugs.ATC.R.R01AA05| name: | Oxymetazoline |
| ATC code: | R01AA05 | route: | intranasal |
| n-compartments | 1 |
Oxymetazoline is an imidazoline decongestant, primarily used as a topical nasal spray for temporary relief of nasal congestion due to common cold, hay fever, or allergies. It acts as an alpha-adrenergic agonist leading to vasoconstriction. Oxymetazoline is available in over-the-counter formulations and is still approved for use today.
There are very limited published data on the pharmacokinetic parameters of oxymetazoline in humans, especially after intranasal administration. No full pharmacokinetic profile with explicit parameters based on published population PK models is available in the literature.
Cacek, AT, et al., & Gopalakrishnan, M (2017). Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. Journal of clinical pharmacology 57(2) 247–254. DOI:10.1002/jcph.799 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27436060
Kaessner, N, et al., & Lahu, G (2012). Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain. International journal of clinical pharmacology and therapeutics 50(9) 665–677. DOI:10.5414/CP201737 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22784611
Cartabuke, RS, et al., & Tobias, JD (2019). Hemodynamic and pharmacokinetic analysis of oxymetazoline use during nasal surgery in children. The Laryngoscope 129(12) 2775–2781. DOI:10.1002/lary.27760 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30786035